ASLAN Pharmaceuticals Ltd
DelistedCIK 1722926fmd_1JSASCTAQPT8JADCNXQKDS3551Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2023, 16 periods
Latest annual · FY2023
Millions- Total revenues
- 12
- Gross profit
- 12
- Operating income
- (44)
- Net income
- (44)
- Free cash flow
- (47)
Latest quarter · Q4 FY2020
Millions- Operating income
- (6)
- Net income
- (6)
- Free cash flow
- (5)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
ASLAN Pharmaceuticals Ltd financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $12 million | $0 | 20-F 2024-04-12 · proof | |
| Gross profit | $12 million | 20-F 2024-04-12 · proof | ||
| Operating income | -$43.7 million | -$47.9 million | 20-F 2024-04-12 · proof | |
| Net income | -$44.2 million | -$51.4 million | 20-F 2024-04-12 · proof | |
| Cash from operating activities | -$46.6 million | -$38.4 million | 20-F 2024-04-12 · proof | |
| Free cash flow | -$46.6 million | -$38.4 million | 20-F 2024-04-12 · proof | |
| Total assets | $24.6 million | $61.2 million | -59.8% | 20-F 2024-04-12 · proof |
| Total liabilities | $37.9 million | $52.8 million | -28.2% | 20-F 2024-04-12 · proof |
| Cash and cash equivalents | $21.3 million | $56.9 million | -62.7% | 20-F 2024-04-12 · proof |
| Total debt | $26.6 million | $37.4 million | -28.9% | 20-F 2024-04-12 · proof |
- What was ASLAN Pharmaceuticals Ltd's revenue in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported revenue of $12 million for fiscal 2023 (the year ended Dec 31, 2023), against $0 the year before. Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What was ASLAN Pharmaceuticals Ltd's gross profit in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported gross profit of $12 million for fiscal 2023 (the year ended Dec 31, 2023). Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What was ASLAN Pharmaceuticals Ltd's operating income in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported operating income of -$43.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$47.9 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What was ASLAN Pharmaceuticals Ltd's net income in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported net income of -$44.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$51.4 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What was ASLAN Pharmaceuticals Ltd's cash from operating activities in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported cash from operating activities of -$46.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -$38.4 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What was ASLAN Pharmaceuticals Ltd's free cash flow in fiscal 2023?
- ASLAN Pharmaceuticals Ltd reported free cash flow of -$46.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -$38.4 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What are ASLAN Pharmaceuticals Ltd's total assets?
- As of Dec 31, 2023, ASLAN Pharmaceuticals Ltd reported total assets of $24.6 million, against $61.2 million a year earlier (-59.8%). Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What are ASLAN Pharmaceuticals Ltd's total liabilities?
- As of Dec 31, 2023, ASLAN Pharmaceuticals Ltd reported total liabilities of $37.9 million, against $52.8 million a year earlier (-28.2%). Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What are ASLAN Pharmaceuticals Ltd's cash and cash equivalents?
- As of Dec 31, 2023, ASLAN Pharmaceuticals Ltd reported cash and cash equivalents of $21.3 million, against $56.9 million a year earlier (-62.7%). Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
- What is ASLAN Pharmaceuticals Ltd's total debt?
- As of Dec 31, 2023, ASLAN Pharmaceuticals Ltd reported total debt of $26.6 million, against $37.4 million a year earlier (-28.9%). Source: the 20-F filed with the SEC on Apr 12, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1722926&period_type=annual&limit=5"Information only, not investment advice.